文献速递胸部肿瘤

Tarlatamab——首创DLL3靶向双特异性T细胞衔接分子——在复发性小细胞肺癌中的开放标签I期研究

Tarlatamab, a First-in-Class DLL3-Targeted Bispecific T-Cell Engager, in Recurrent Small-Cell Lung Cancer: An Open-Label, Phase I Study.
PubMed 文献 · J Clin Oncol · 2023-01-23

该开放标签I期研究评估了Tarlatamab在复发/难治性小细胞肺癌(SCLC)患者中的安全性和抗肿瘤活性。107例患者接受治疗,客观缓解率为23.4%(95%CI 15.7-32.5),中位缓解持续时间12.3个月(95%CI 6.6-14.9),安全性总体可控。

要点

  • Tarlatamab在重度经治SCLC中客观缓解率23.4%,中位缓解持续时间12.3个月。
  • 细胞因子释放综合征最常见(52%),3级仅1%;1例(1%)发生5级肺炎。
  • 探索性分析提示选择DLL3高表达患者可能获得更多临床获益。

核心结论

  • 在重度经治的复发性小细胞肺癌患者中,Tarlatamab显示出可控的安全性和令人鼓舞的缓解持久性。
  • 作者认为这一有前景的分子需进一步评估,相关研究正在进行中。

研究设计与样本

  • 开放标签I期研究,评估Tarlatamab在复发/难治性小细胞肺癌患者中的安全性和疗效。
  • 截至2022年7月19日,107例患者接受Tarlatamab治疗,剂量探索队列(0.003至100 mg)73例,扩展队列(100 mg)34例。
  • 主要终点为安全性;次要终点包括按改良RECIST 1.1评估的抗肿瘤活性、总生存和药代动力学。

主要发现

  • 既往抗癌治疗中位线数为2线(范围1-6线),49.5%的患者接受过抗PD-1/PD-L1治疗。
  • 任何级别治疗相关不良事件发生于97例(90.7%),≥3级发生于33例(30.8%);1例(1%)发生5级肺炎。
  • 细胞因子释放综合征为最常见的治疗相关不良事件,发生于56例(52%),其中3级1例(1%)。
  • 未达到最大耐受剂量。
  • 客观缓解率为23.4%(95%CI 15.7-32.5),包括2例完全缓解和23例部分缓解;中位缓解持续时间为12.3个月(95%CI 6.6-14.9)。

临床怎么用

  • 原文未据此给出推荐。

局限性

  • 原文未报告局限性。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

PURPOSE: Small-cell lung cancer (SCLC) is an aggressive malignancy with limited treatments. Delta-like ligand 3 (DLL3) is aberrantly expressed in most SCLC. Tarlatamab (AMG 757), a bispecific T-cell engager molecule, binds both DLL3 and CD3 leading to T-cellb-mediated tumor lysis. Herein, we report phase I results of tarlatamab in patients with SCLC. PATIENTS AND METHODS: This study evaluated tarlatamab in patients with relapsed/refractory SCLC. The primary end point was safety. Secondary end points included antitumor activity by modified RECIST 1.1, overall survival, and pharmacokinetics. RESULTS: By July 19, 2022, 107 patients received tarlatamab in dose exploration (0.003 to 100 mg; n = 73) and expansion (100 mg; n = 34) cohorts. Median prior lines of anticancer therapy were 2 (range, 1-6); 49.5% received antiprogrammed death-1/programmed death ligand-1 therapy. Any-grade treatment-related adverse events occurred in 97 patients (90.7%) and grade b % 3 in 33 patients (30.8%). One patient (1%) had grade 5 pneumonitis. Cytokine release syndrome was the most common treatment-related adverse event, occurring in 56 patients (52%) including grade 3 in one patient (1%). Maximum tolerated dose was not reached. Objective response rate was 23.4% (95% CI, 15.7 to 32.5) including two complete and 23 partial responses. The median duration of response was 12.3 months (95% CI, 6.6 to 14.9). The disease control rate was 51.4% (95% CI, 41.5 to 61.2). The median progression-free survival and overall survival were 3.7 months (95% CI, 2.1 to 5.4) and 13.2 months (95% CI, 10.5 to not reached), respectively. Exploratory analysis suggests that selecting for increased DLL3 expression can result in increased clinical benefit. CONCLUSION: In patients with heavily pretreated SCLC, tarlatamab demonstrated manageable safety with encouraging response durability. Further evaluation of this promising molecule is ongoing.

来源:J Clin Oncol,查看原文。版权归原作者所有。

引用

  1. Paz-Ares L, Champiat S, Lai WV, et al. Tarlatamab, a First-in-Class DLL3-Targeted Bispecific T-Cell Engager, in Recurrent Small-Cell Lung Cancer: An Open-Label, Phase I Study. J Clin Oncol. 2023. PMID: 36689692. doi:10.1200/JCO.22.02823

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。